Micro-RNAs Predict Response to Systemic Treatments in Metastatic Renal Cell Carcinoma Patients: Results from a Systematic Review of the Literature

Locally advanced or metastatic renal cell carcinomas (mRCCs) account for up to 15% of all kidney cancer diagnoses. Systemic therapies (with or without surgery) represent gold standard treatments, mostly based on tyrosine kinase inhibitors in association with immunotherapy. We provide an overview of...

Descripción completa

Detalles Bibliográficos
Autores principales: Monti, Martina, Lunardini, Susanna, Magli, Igino Andrea, Campi, Riccardo, Primiceri, Giulia, Berardinelli, Francesco, Amparore, Daniele, Terracciano, Daniela, Lucarelli, Giuseppe, Schips, Luigi, Ferro, Matteo, Marchioni, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220270/
https://www.ncbi.nlm.nih.gov/pubmed/35740309
http://dx.doi.org/10.3390/biomedicines10061287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220270/
https://www.ncbi.nlm.nih.gov/pubmed/35740309
http://dx.doi.org/10.3390/biomedicines10061287

Ejemplares similares